Respondents contributed from Austria, Belgium, The Netherlands, Denmark, Finland, Norway, Sweden and Switzerland

* Public survey open to every one in The Netherlands, Denmark, Finland, Norway, Sweden and Switzerland, 821 adults responded:predominantly patients and carers, healthcare & pharma professionals.

A1. To what extent do you agree or disagree with the following statements about pharmaceutical companies? [1=Strongly disagree, 2=Tend to disagree, 3=Neither agree nor disagree, 4=Tend to agree, 5=Strongly agree,
Don’t know, Prefer not to say] (adults who responded: predominantly patients and carers, healthcare & pharma professionals. n=821)

A2. To what extent do you agree or disagree that pharmaceutical companies should do the following? A3. To what extent do you agree or disagree with these statements about Bristol Myers Squibb (BMS)? [1=Strongly disagree,
2=Tend to disagree, 3=Neither agree nor disagree, 4=Tend to agree, 5=Strongly agree, Don’t know, Prefer not to say] (adults who responded: predominantly patients and carers, healthcare & pharma professionals. n=821)

A1. To what extent do you agree or disagree with the following statements about pharmaceutical companies? A2. To what extent do you agree or disagree that pharmaceutical companies should do the following? [1=Strongly disagree,
2=Tend to disagree, 3=Neither agree nor disagree, 4=Tend to agree, 5=Strongly agree, Don’t know, Prefer not to say] (adults who responded: predominantly patients and carers, healthcare & pharma professionals. n=821)

A1. To what extent do you agree or disagree with the following statements about pharmaceutical companies? [1=Strongly disagree, 2=Tend to disagree, 3=Neither agree nor disagree, 4=Tend to agree, 5=Strongly agree,
Don’t know, Prefer not to say] (adults who responded: predominantly patients and carers, healthcare & pharma professionals. n=821)

B3. Which, if any, of the following people or groups do you think pharmaceutical companies should be cooperating with more? (select up to five responses from a list of 12) (adults who responded:predominantly patients and carers, healthcare & pharma professionals. n=821)

A1. To what extent do you agree or disagree with the following statements about pharmaceutical companies? [1=Strongly disagree, 2=Tend to disagree, 3=Neither agree nor disagree, 4=Tend to agree, 5=Strongly agree, Don’t know,
Prefer not to say] B3. Which, if any, of the following people or groups do you think pharmaceutical companies should be cooperating with more? (select up to five responses from a list of 12) (adults who responded: predominantly
patients and carers, healthcare & pharma professionals. n=821)

What the public told us

What more can we do?
We asked survey respondents:
How can pharma companies better support
patients and local communities: what are
your ideas for projects and activities?
Here are some of people’s suggestions:(The word cloud shows the most frequently mentioned words from all
responses. The larger the word, the more frequently it was mentioned.
Hover your mouse over key words to discover some specific suggestions.)

B4. Apart from the discovery and provision of medicines, please could you share any ideas you have for specific projects or activities that pharmaceutical companies could conduct to better help support patients or local communities? Open text question

•
•
•

Thank you for these valuable insights.

* Online study with 214 oncology or atrial fibrillation patients and caregivers of patients with those conditions in Austria, Belgium, The Netherlands, Denmark, Finland, Norway, Sweden and Switzerland;
all countries weighted equally. Exploratory qualitative research was also done with 40 patient advocacy groups. For full details, please see the Annex

Symptom awareness

Diagnosis

Treatment plan

Follow-up

Present day

25%
Insights from patient groups

Qualitative research* Those who tend to agree or strongly agree that pharmaceutical companies should support activities in partnership with patient groups, or other pharmaceutical companies, or aim to support patients beyond medicinal treatment.
B4. You indicated that pharma companies should invest in meaningful local activities, please select which of the following, you would like to see investment into the most. Base: n=831. Those HCPs who selected that pharmacompanies should support activities with patient groups/other pharma companies/support beyond medicinal treatment

Symptom awareness

Diagnosis

Treatment plan

Follow-up

Present day

38%

Insights from patient groups

Qualitative research

QA1. Select item importance (pick max. 5 items out of 28) - Which of the following stages would you say present the most challenges to you as a physician? Base: Total n=839 physicians

Symptom awareness

Diagnosis

Treatment plan

Follow-up

Present day

23%

25%
Insights from patient groups

Qualitative research

QA2. Select item importance (pick max. 5 items out of 23) - which of the following stages, would you say were the most challenging for you/the person you care for with this condition? Base: Patients/caregivers (n=214)
QA1. Select item importance (pick max. 5 items out of 28) - Which of the following stages would you say present the most challenges to you as a physician? Base: Total n=839 physicians

Symptom awareness

Diagnosis

Treatment plan

Follow-up

Present day

23%

14%
Insights from patient groups

Qualitative research

QA5. Statement ranking (23 statements) - which of the following stages, would you/the person you care for have appreciated more support? Base: Patients/caregivers (n=214)
QA4. Select item importance (pick max. 5 items out of 28) - At which of the following stages would you like to be able to provide more support to your patients? Base: Total n=839 physicians

Symptom awareness

Diagnosis

Treatment plan

Follow-up

Present day

26%

11%

QA4. At which of the following stages, if any, would you like to be able to provide more support to your patients beyond the provision of medicines and surgery, but are unable to do so currently? [select up to five from a list of 28]
Base: n=839 (All physicians)
Select item importance (pick max. 5 items out of 23) - which of the following stages, would you say were the most challenging for you/the person you care for with this condition? Base patients/caregivers n=214)

Symptom awareness

Diagnosis

Treatment plan

Follow-up

Present day

25%
24%
Insights from patient groups••

QA2. Select item importance (pick max. 5 items out of 23) - which of the following stages, would you say were the most challenging for you/the person you care for with this condition? Base: Patients/caregivers (n=214)
QA1. Select item importance (pick max. 5 items out of 28) - Which of the following stages would you say present the most challenges to you as a physician? Base: Total n=839 physicians

Qualitative researchSymptom awareness

Diagnosis

Treatment plan

Follow-up

Present day

22%
19%
Insights from patient groups

Qualitative research

QA2. Select item importance (pick max. 5 items out of 23) - which of the following stages, would you say were the most challenging for you/the person you care for with this condition? Base: Patients/caregivers (n=214)
QA5. Statement ranking (23 statements) - which of the following stages, would you/the person you care for have appreciated more support? Base: Patients/caregivers (n=214)

Symptom awareness

Diagnosis

Treatment plan

13%

26%

28%

13%

Follow-up

Present day

Insights from patient groups

Qualitative research

A1. Thinking about your experience of treating and managing your pts, which of the following stages would you say present the most challenges to you as a physician? [select up to 5 from a list of 28] Base: n=839 (All physicians) A4. At which of
the following stages, if any, would you like to be able to provide more support to your patients beyond the provision of medicines and surgery, but are unable to do so currently? [select up to 5 from a list of 28] Base: n=839 (All physicians)
A5. At which of the following stages, if any, do you think [PN: PATIENT INSERT you] [PN: CARER INSERT the person you care for] would have appreciated more support? [select up to 5 from a list of 23] Base=214 (All patients/caregivers)

Symptom awareness

Diagnosis

Treatment plan

Follow-up

Present day

28%
30%
Insights from patient groups

Qualitative research

QA2. Select item importance (pick max. 5 items out of 23) - which of the following stages, would you say were the most challenging for you/the person you care for with this condition? Base: Patients/caregivers (n=214)
QA4. At which of the following stages, if any, would you like to be able to provide more support to your patients beyond the provision of medicines and surgery, but are unable to do so currently? [select up to 5 from a list of 28]
Base: n=839 (All physicians)

Symptom awareness

Diagnosis

Treatment plan

Follow-up

Present day

41%
24%
Insights from patient groups

Qualitative research

QA1. Select item importance (pick max. 5 items out of 28) - Which of the following stages would you say present the most challenges to you as a physician? Base: Total n=839 physicians
A8. Which of the following services, if any, would you/the person you care for like access to? Base: Total patients/caregivers n=214

58%
•
•

35%
40%
26%
1%
1%

2%
1%

5%
1%

Don't know

Prefer not to say

No knowledge at all

B1/B1. Overall, how would you rate your knowledge of pharmaceutical companies? Base: Total patients/caregivers n=214, physicians n=839

17%
13%

Not very much knowledge

A fair amount ofknowledge

A great deal of knowledge

6%

A6. Which stakeholders, if any are important in supporting/partnering with you when it comes to providing overall patient care? [Select up to three responses from a list of 14] Base: n=839 physicians

94%
88%
86%
85%
85%

82%
81%
80%
79%
78%

B3/B4. To what extent do you agree or disagree that pharmaceutical companies should do the following? [1=Strongly disagree, 2=Tend to disagree, 3=Neither agree nor disagree, 4=Tend to agree, 5=Strongly agree,
Don’t know, Prefer not to say] (Total patients/caregivers n= 214, physicians n=839)

Symptom awareness

Diagnosis

Treatment plan

Follow-up

Present day

21%
23%
23%
Insights from patient groups

Qualitative research

QC2. Select item importance (pick max. 5 items out of 13) – Which, if any, of the following services would you like to see better supported by pharmaceutical companies? Base: Patients/caregivers (n=214)
QA7. Select item importance (pick max. 5 items from 19) - Which, if any, of the following services would improve patients’ experiences living with their conditions? Base: Physicians (n=839)

Symptom awareness

Diagnosis

Treatment plan

Follow-up

Present day

Potential to build physicians' capacity; create new tools & services

22%
38%
54%
Insights from patient groups

Qualitative research

C3. Which, if any, of the following people or groups do you think pharmaceutical companies should be cooperating with more? (pick max. 5 items from 12) – People or groups patients and caregivers think pharma should be cooperating withmore Base: Patients/caregivers (n=214) A9. Beyond medication, which if any, of these unmet needs do you think could be addressed in collaboration with the pharmaceutical industry to support your patients? Base: Physicians who think
there are needs that can be addressed by pharma (n=792)

Symptom awareness

Diagnosis

Treatment plan

Follow-up

Present day

25%
10%
20%
Insights from patient groups

Qualitative research

A8. Which of the following services would you/the person you care for like access to? (pick max. 5 items out of 19) Base: Patients/caregivers (n=214)
QA7. Select item importance (pick max. 5 items from 19) - Which, if any, of the following services would improve patients’ experiences living with their conditions? Base: Physicians (n=839)

Symptom awareness

Diagnosis

Treatment plan

Follow-up

Present day

28%
31%
31%
Insights from patient groups

Qualitative research

QA4. Select item importance (pick max. 5 items out of 28) - At which of the following stages, if any, would you like to be able to provide more support to your patients beyond the provision of medicines and surgery, but are unable to do socurrently? Base: Total n= 839 Physicians QC2. Select item importance (pick max. 5 items out of 13) – Which, if any, of the following services would you like to see better supported by pharmaceutical companies? Base: Patients/caregivers (n=214)

Symptom awareness

Diagnosis

Treatment plan

Follow-up

Present day

19%
14%
Insights from patient groups

Qualitative research

A9. Beyond medication, which if any, of these unmet needs do you think could be addressed in collaboration with the pharmaceutical industry to support your patients? Base: Physicians who think there are needs that can be addressed bypharma (n=792) QC2. Select item importance (pick max. 5 items out of 13) – Which, if any, of the following services would you like to see better supported by pharmaceutical companies? Base: Patients/caregivers (n=214)

Symptom awareness

Diagnosis

Treatment plan

22%

27%

23%

12%

Follow-up

Present day

Insights from patient groups

Qualitative research

QA7. Select item importance (pick max. 5 items from 19) - Which, if any, of the following services would improve patients’ experiences living with their conditions? Base: Physicians (n=839)
QC2. Select item importance (pick max. 5 items out of 13) - Which, if any, of the following services would you like to see better supported by pharmaceutical companies? Base: Patients/caregivers (n=214)

Symptom awareness

Diagnosis

Treatment plan

Follow-up

Present day

24%
23%
Insights from patient groups

Qualitative research

QC2. Select item importance (pick max. 5 items out of 13) – Which, if any, of the following services would you like to see better supported by pharmaceutical companies? Base: Patients/caregivers (n=214)Technical Note – Healthcare Professional Survey
On behalf of Bristol Myers Squibb, Ipsos MORI carried out an online survey
with a sample of 839 healthcare professionals (primary care physicians,
cardiologists and oncologists/haematologists) across eight European
countries (Austria, Belgium, Denmark, Finland, Netherlands, Norway,
Sweden, Switzerland). Online surveys were conducted between 11th
January 2021 and 26th April 2021.

Technical Note – Patient and Caregiver Survey
On behalf of Bristol Myers Squibb, Ipsos MORI carried out an online survey
with a sample of 214 patients and caregivers (oncology patients, oncology
caregivers, atrial fibrillation patients, atrial fibrillation caregivers) acrosseight European countries (Austria, Belgium, Denmark, Finland,
Netherlands, Norway, Sweden, Switzerland). Online surveys wereconducted between 11th January 2021 and 26th April 2021.
Respondents were recruited via online panels, and as such, the sample
contains respondents who are engaged with market research panels andchose to take part in the survey.
The sample includes the following per country:
AT

BE

DK

FI

NL

NO

SE

CH

Total

30

30

20

30

30

15

29

30

Oncology
patients

8

8

8

8

8

10

8

8

Oncology
caregivers

7

7

7

7

7

5

7

7

Atrialfibrillation
patients

8

Atrialfibrillation
caregivers

7

8

7

3

2

8

7

8

7

0

0

8

6

The sample includes the following per country:
AT

BE

DK

FI

NL

NO

SE

CH

Total

105

120

100

93

120

70

116

115

PCPs

50

50

50

51

50

42

50

50

Cardiologists

30

40

30

22

40

18

40

40

Oncologists/haematologists

25

30

20

20

30

10

26

25

When reporting on country results, survey data are weighted to ensure
equal contribution from primary care physicians, cardiologists andoncologists/haematologists. When reporting on total results survey data
are additionally weighted to ensure equal contribution per country.

8

7

When reporting on country results survey data are weighted to ensure
equal contribution of oncology patients/caregivers and atrial fibrillation
patient/caregivers within a country*. When reporting at a total level data
are additionally weighted to ensure equal contribution per country.
* Except in Norway, where the sample consists only of oncology
patients/caregivers, and so no weighting was applied.

Respondents were recruited via online panels, and as such, the sample
contains respondents who are engaged with market research panels andchose to take part in the survey.

Technical Note - Patient Advisory Group Qualitative Research:
On behalf of Bristol Myers Squibb, Ipsos MORI conducted exploratory
qualitative research in eight European markets (Austria, Belgium,
Denmark, Finland, Netherlands, Norway, Sweden, Switzerland). In total,
40 respondents completed a web-assisted telephone in-depth interview(37 respondents were working for an oncology patient advisory group, 3
for an atrial fibrillation patient advisory group). Respondents wererecruited via telephone through third party panel providers. Interviews
were carried out between 11th January 2021 and 26th April 2021.
Please note that this qualitative research approach explores the range of
attitudes and opinions of participants in detail and that the findings aredescriptive and illustrative, not statistically representative.

Technical Note – Single-blinded Open Invitation Digital ‘Humanity’ Survey:
On behalf of Bristol Myers Squibb, Ipsos MORI carried out an online survey
with a sample of 821 adults aged 16 and over, across nine European countries(Austria, Belgium, Denmark, Finland, Luxembourg, Netherlands, Norway,
Sweden, Switzerland). Interviews were conducted between 20th November
2020 and 18th January 2021.
Respondents were invited to respond to an open invitation from Bristol Myers
Squib to share their views and suggestions on their opinions of thepharmaceutical industry, pharmaceuticals companies and the challenges they
face regarding healthcare provision in their country. This invitation wasshared in a range of paid advertising channels on websites and social media,
but also direct emails and organic posts:• paid post on LinkedIn;• organic posts on LinkedIn;• direct email to BMS employees;• hosting on Bristol Myers Squibb websites.
As such, the sample includes a mix of respondents who responded to theonline campaign and chose to take part and is not a representative sample ofthe population of the countries included in the campaign. It is also likely
respondents are already engaged with Bristol Myers Squib and/or thepharmaceutical industry in general. The sample includes members of the
public, patients, caregivers, healthcare professionals, pharmaceuticalindustry employees and their friends and family. Results are indicative innature and reflect the responses of the survey participants only. Participants
outside of the countries listed were screened out and could not participate.
In total there were 129,688 clicks onto the survey, with 821 respondents
completing the survey.
The sample includes the following per country:
AT

BE

DK

FI

LU

NL

NO

SE

CH

Total

82

325

33

30

0

193

35

55

68

Healthcare
professionals

20

60

14

11

0

19

9

10

16

Patients or
caregivers

16

105

8

6

0

79

11

13

19

Pharmacompany
employees

22

96

4

8

0

39

7

7

24

Other

34

119

13

14

0

79

12

33

23

When reporting on global results, all participants are included and noweighting has been applied to the data

Because there is more to do

We are listening

We have heard you

Let’s act together!

NO-BE-2100019 – NO-CH-2100056 – NO-DK-2100008 – NO-FI-2100007 – NO-NL-2100024 – NO-NO-2100002 – NO-SE-2100011